JP2010505831A5 - - Google Patents

Download PDF

Info

Publication number
JP2010505831A5
JP2010505831A5 JP2009531418A JP2009531418A JP2010505831A5 JP 2010505831 A5 JP2010505831 A5 JP 2010505831A5 JP 2009531418 A JP2009531418 A JP 2009531418A JP 2009531418 A JP2009531418 A JP 2009531418A JP 2010505831 A5 JP2010505831 A5 JP 2010505831A5
Authority
JP
Japan
Prior art keywords
peptide
amino acid
pharmaceutical composition
amino acids
capsid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009531418A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010505831A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/021156 external-priority patent/WO2008045238A2/en
Publication of JP2010505831A publication Critical patent/JP2010505831A/ja
Publication of JP2010505831A5 publication Critical patent/JP2010505831A5/ja
Pending legal-status Critical Current

Links

JP2009531418A 2006-10-05 2007-10-02 安定化した、治療用の小型のヘリックス性抗ウイルスペプチド Pending JP2010505831A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84955106P 2006-10-05 2006-10-05
PCT/US2007/021156 WO2008045238A2 (en) 2006-10-05 2007-10-02 Stabilized therapeutic small helical antiviral peptides

Publications (2)

Publication Number Publication Date
JP2010505831A JP2010505831A (ja) 2010-02-25
JP2010505831A5 true JP2010505831A5 (enExample) 2011-07-14

Family

ID=39283347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009531418A Pending JP2010505831A (ja) 2006-10-05 2007-10-02 安定化した、治療用の小型のヘリックス性抗ウイルスペプチド

Country Status (8)

Country Link
US (1) US8940864B2 (enExample)
EP (2) EP2517720A1 (enExample)
JP (1) JP2010505831A (enExample)
AU (1) AU2007307254A1 (enExample)
CA (1) CA2665186A1 (enExample)
ES (1) ES2387827T3 (enExample)
WO (1) WO2008045238A2 (enExample)
ZA (1) ZA200901248B (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937154B2 (en) 2006-10-05 2015-01-20 New York Blood Center, Inc. Stabilized therapeutic small helical antiviral peptides
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
CA2682174C (en) 2007-03-28 2021-04-06 President And Fellows Of Harvard College Stitched polypeptides
AU2009244400B2 (en) * 2008-05-06 2012-12-20 New York Blood Center Antiviral cell penetrating peptides
JP2012503024A (ja) * 2008-09-22 2012-02-02 エルロン・セラピューティクス・インコーポレイテッド ペプチド模倣大環状分子
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
RU2639523C2 (ru) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы и их применение
WO2013123266A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2819688A4 (en) 2012-02-15 2015-10-28 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
CN104812384B (zh) 2012-11-01 2020-09-18 爱勒让治疗公司 二取代的氨基酸及其制备和使用方法
US11039620B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US9622483B2 (en) 2014-02-19 2017-04-18 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
US11039621B2 (en) 2014-02-19 2021-06-22 Corning Incorporated Antimicrobial glass compositions, glasses and polymeric articles incorporating the same
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
SG10201902598VA (en) 2014-09-24 2019-04-29 Aileron Therapeutics Inc Peptidomimetic macrocycles and formulations thereof
KR101972012B1 (ko) * 2014-11-28 2019-04-24 서울대학교산학협력단 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2017018595A1 (ko) * 2015-07-28 2017-02-02 동국대학교 산학협력단 이중 스테이플화된 펩타이드 및 이의 용도
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
US11279734B2 (en) 2017-12-01 2022-03-22 Massachusetts Institute Of Technology Solution-phase affinity selection of inhibitors from combinatorial peptide libraries
US20200102356A1 (en) * 2018-10-01 2020-04-02 NMC Inc. Compositions and Methods for the Treatment of Huanglongbing (HLB) aka Citrus Greening in Citrus Plants
WO2022036049A2 (en) * 2020-08-12 2022-02-17 New York Blood Center, Inc. Antiviral stapled peptides against sars-cov-2

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187548B1 (en) * 1993-05-23 2001-02-13 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods using human calcium sensor protein, fragments thereof and DNA encoding same
US6239270B1 (en) * 1993-05-24 2001-05-29 Rhone-Poulenc Rorer S.A. Nucleic acids encoding human calcium sensor protein
US6790950B2 (en) * 1999-04-09 2004-09-14 Pharmacia & Upjohn Company Anti-bacterial vaccine compositions
ES2439645T3 (es) * 1999-04-09 2014-01-24 Zoetis P&U Llc Bacteria pasteurelácea atenuada que tiene una mutación en un gen de virulencia
US7192713B1 (en) * 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
US6653102B2 (en) * 2000-10-17 2003-11-25 Myriad Genetics, Inc. Nucleic acid encoding a phosphatase 2C that interacts with Fe 65
EP1680443B9 (en) * 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
WO2008008998A2 (en) * 2006-07-13 2008-01-17 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in signaling pathways
US20100159477A1 (en) * 2006-07-13 2010-06-24 Peter Hornbeck Reagents for the detection of protein phosphorylation in signaling pathways
KR20090059148A (ko) * 2006-09-11 2009-06-10 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신 유래된 펩티드의 변형 및 이의 이용 방법
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
JP5078401B2 (ja) * 2007-03-27 2012-11-21 株式会社Adeka 防水シート
CA2700925C (en) * 2007-09-26 2016-08-23 Dana Farber Cancer Institute Methods and compositions for modulating bcl-2 family polypeptides
EP2247606B1 (en) * 2008-01-23 2019-08-21 Dana-Farber Cancer Institute, Inc. Compositions and methods for the treatment of viral infections
AU2009244400B2 (en) * 2008-05-06 2012-12-20 New York Blood Center Antiviral cell penetrating peptides
EP3401684B1 (en) * 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides

Similar Documents

Publication Publication Date Title
JP2010505831A5 (enExample)
JP7362142B2 (ja) 環状ntcp標的化ペプチドおよび侵入阻害剤としてのその使用
JP2010510236A5 (enExample)
Sulkowski et al. Boceprevir plus peginterferon/ribavirin for the treatment of HCV/HIV co-infected patients
Berkhout et al. Is there a future for antiviral fusion inhibitors?
RU2008126305A (ru) Новый пептид
JP2012521201A5 (enExample)
JP2003535043A5 (enExample)
JP2011006428A5 (enExample)
JP2012503011A5 (ja) 慢性c型肝炎ウイルス感染症のための酵母系免疫治療組成物
JP2008508859A5 (enExample)
KR102599942B1 (ko) Hbv 및 hdv 감염의 조합 치료법
JP2010500399A5 (enExample)
JP2014111628A (ja) ウイルス融合のインヒビターのコレステロール誘導体
JP2012504602A5 (enExample)
Redman et al. Pharmacokinetic and chemical synthesis optimization of a potent D-peptide HIV entry inhibitor suitable for extended-release delivery
RU2014111179A (ru) КОНЪЮГАТЫ ИНТЕРФЕРОНА λ1 И ПОЛИЭТИЛЕНГЛИКОЛЯ
JP2014525939A5 (enExample)
JP2009510134A5 (enExample)
WO2007137591A8 (en) Hiv vaccine
JP2010511706A5 (enExample)
JP6910043B2 (ja) ヘマグルチニン結合ペプチド、および、これを含むインフルエンザウイルス感染症の予防・治療薬
CN118615306A (zh) 一种抑制病毒感染的药物组合物及其应用
WO2023196913A2 (en) Methods of treating ankylosing spondylitis
AU1906592A (en) Peptides for use in induction of t cell activation against hiv-1